Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ValiRx has entered into a license agreement with Cancer Research Technology to evaluate a novel prostate cancer compound, VAL201 that has been found in vivo to arrest prostate cancer growth.
Subscribe to our email newsletter
Under the terms of the license agreement with Cancer Research Technology (CRT), ValiRx has a period of 12 months in which to complete the pre-clinical regulatory development of VAL201 including toxicology, prior to exercising its option to acquire exclusive worldwide rights to the compound as an anti-cancer agent and subsequently progress to clinical trials.
Satu Vainikka, CEO of ValiRx, said: “This agreement further extends our relationship with CRT and expands our portfolio of late pre-clinical compounds. If successful, VAL 201 could offer the potential for novel treatment approaches to prostate cancer treatment where there is currently unmet need.”